THURSDAY | AUGUST 13, 2020
|
|
COVID Antigen Tests: Coming to Case Counts Near You?
— New guidance from national epidemiology group could remake surveillance
The group will emphasize that positive rapid antigen tests should be counted in daily tallies, which many states such as Texas and California currently do not include.
They can be included with counts of either probable or confirmed cases, at states' discretion -- but they should be counted, said Jeffrey Engel, MD, the CSTE's senior advisor on COVID response, and its past executive director.
|
|
ASIPP® Annual Meeting 2020 Goes Virtual
Due to unavoidable circumstances related to COVID-19, ASIPP is transitioning its annual meeting scheduled September 4-6, 2020, in Dallas, Texas to a virtual meeting. This will provide you with many advantages:
- Save time and money: More time in the office with patients and no fear of Covid exposure.
- Attend the meeting from wherever you want.
- Get back on track with your CMEs.
- Revisit the sessions and explore exhibit booths even after the meeting ends. Virtual platform access will remain open until the summer of 2021.
- Same great networking opportunities in virtual platform: Ability to host and request private meetings; talk with others while you visit exhibit booths, and so much more!
- Still offering world-renowned speakers on relevant subjects to IPM, COVID-19 interfacing with IPM, and many other subjects including opioids and regenerative medicine.
- Meeting kicks off with a presentation by a well-known figure in the industry, Randy Alvarez, President and CEO of Wellness Hour.
If you have already registered for the Annual Meeting, your registration fee has been transferred to the Virtual Annual Meeting. There is nothing you need to do now. You will receive information on how to attend the meeting in August.
|
|
Order Now - Recorded Virtual Review Courses
The following courses are offered:
- Documentation, Coding, Compliance, and Practice Management Review Course
- Controlled Substance Management Review Course
- *Pain Medicine and Interventional Pain Management Comprehensive Review Course
*not available until the end of the live course July 26, 2020
|
|
ABIPP Recognizes Your Knowledge and Expertise
The American Board of Interventional Pain Physicians (ABIPP) has developed certification programs that recognize accepted levels of knowledge and expertise in the interventional pain management profession, with the goal of improved patient care. Hundreds of qualified physicians have made the commitment to become ABIPP certified.
ABIPP now offers the only competency
certification program for regenerative medicine.
For complete information about the examination requirements and to obtain an application packet, visit www.abipp.org or call 270-554-9412 x4217 or by email at summer@asipp.org.
|
|
TESTS OFFERED
ABIPP Part I - Theoretical written exam - TBD
ABIPP Part II - Oral and Hands-on practical exam - TBD
ABIPP Competency Exam - includes written, oral, and hands-on practical examinations TBD
Combined CSM/CCPM Exam for ABIPP Path – TBD
Competency Exam in Controlled Substance Management – TBD
Competency Exam in Coding, Compliance, and Practice Management - TBD
Regenerative Medicine Competency Exam - includes written, oral, and hands-on practical examinations – TBD
|
|
|
HHS reopens applications for COVID-19 provider assistance
- A new chance to apply for CARES Act grants was offered to providers that previously rejected the funds, among other prospective applicants.
- Some providers returned the initial CARES Act grants.
- New legislation would prevent not-for-profit providers from owing taxes on the grants.
Providers that rejected or missed applying for federal grants to mitigate revenue shortfalls from the COVID-19 pandemic will have another chance to apply.
The U.S. Department of Health and Human Services (HHS) on Aug. 10 announced it has reopened the application process, which had closed June 3, for providers to garner Provider Relief Fund (PRF) payments.
The assistance from the $50 billion general-distribution fund created by the Coronavirus Aid, Relief and Economic Security (CARES) Act is open to:
- Providers that rejected and returned the initial funding but are now interested in obtaining funds
- Providers that previously missed applying
- Medicaid and Children’s Health Insurance Program (CHIP) providers
- Dental providers with low Medicare revenues
- Providers with a change in ownership that now makes them eligible
- Providers that did not have Medicare fee-for-service revenue in 2019
Applications for the latest grants, which will provide 2% of a recipient’s total patient care revenue, are due Aug. 28.
|
|
Novel Opioid Gets FDA Nod
— IV oliceridine approved for hospital, controlled clinical settings
WASHINGTON -- Oliceridine (Olinvyk), a novel opioid agonist, won approval to manage moderate to severe acute pain in adults when pain is severe enough to require an intravenous opioid (IV) and when other treatments are inadequate, the FDA announced late Friday.
The drug is indicated for short-term IV use in hospitals or other controlled clinical settings like inpatient and outpatient procedures, not for at-home use.
Oliceridine is a G protein-selective agonist that targets the mu opioid receptor. It was designed to be similar to morphine in reducing pain, but with less risk of respiratory depression and gastrointestinal dysfunction
|
|
Targeted Program Can Improve Adherence to Opioid Prescribing Guidelines
A targeted program that allows all prescribers to access real-time data and track and compare their own performance with those of others can improve adherence to current opioid prescribing guidelines, according to study results published in Arthritis Care & Research.
As part of the efforts to reduce unwarranted opioids prescription, the US Centers for Disease Control and Prevention (CDC) Guidelines for Prescribing Opioids for Chronic Pain for providers recommends a complete risk-benefit assessment before initiating or maintaining opioid therapy.
The Division of Rheumatology at the University of Pennsylvania created a quality improvement program based on electronic health record-integrated data feedback to reduce variability in opioid prescribing and to increase compliance with available guidelines for opioid use for chronic pain. Providers were able to access individualized and division-wide data to assess their performance according to the CDC and local guidelines.
|
|
|
|
July/August 2020
Issue Available
In this issue, Pain Physician includes Systematic Reviews on Interlaminar Epidural Injections, the Scrambler Therapy, and Long-term Outcomes of Epidurals for Lumbar Disc Hernation; Randomized Trials on Bilateral Ultrasound-Guided Erector Spine Plane Block and Contrast Medium Volume needed for Transforaminal Epidural Injections, and more.
|
|
Mohamed Kamal Mesregah, MD, PhD, Wei Feng, PhD, Wei-Hsun Huang, MBBS, Wei-Cheng Chen, MBBS, Brandon Yoshida, BSc, Andrew Mecum, BA, Krishna Mandalia, BSc, and Nicholas Van Halm-Lutterodt, MD, PhD
Wenxing Zhao, MD, PhD, Yong Wang, MD, Jianping Wu, MD, PhD, Xinyou Gao, MD, Quanfeng Wei, MD, Xuezhen Lai, MD, and Jianxiong An, MD, PhD
|
|
COVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020
Summary
What is already known about this topic?
Multisystem inflammatory syndrome in children (MIS-C) is a rare but severe condition that has been reported approximately 2–4 weeks after the onset of COVID-19 in children and adolescents.
What is added by this report?
Most cases of MIS-C have features of shock, with cardiac involvement, gastrointestinal symptoms, and significantly elevated markers of inflammation, with positive laboratory test results for SARS-CoV-2. Of the 565 patients who underwent SARS-CoV-2 testing, all had a positive test result by RT-PCR or serology.
What are the implications for public health practice?
Distinguishing MIS-C from other severe infectious or inflammatory conditions poses a challenge to clinicians caring for children and adolescents. As the COVID-19 pandemic continues to expand in many jurisdictions, health care provider awareness of MIS-C will facilitate early recognition, early diagnosis, and prompt treatment.
|
|
DOJ brings lawsuit against Cigna for allegedly submitting $1.4 billion in false Medicare Advantage claims
The Department of Justice on Tuesday filed a lawsuit against health insurer Cigna alleging that the company submitted fraudulent Medicare Advantage claims to the Centers for Medicare and Medicaid Services.
The suit claims that between 2012 and 2017 Cigna used improper diagnostic codes for health conditions that its members did not have, were not recorded in medical records and were not based on clinically reliable information. Over the course of that time, CMS overpaid Cigna by more than $1.4 billion, according to the DOJ.
"[Cigna] intentionally misrepresented these health conditions as part of a widespread scheme to coax CMS into paying a higher capitated rate on behalf of Medicare beneficiaries enrolled in [Cigna's] Medicare Advantage plans," the DOJ said in its claim.
|
|
ASIPP® Partners with Fedora Billing And Revenue Cycle Management Company
|
|
ASIPP is now able to offer unique benefits for revenue cycle management with billing, etc.
Fedora is a company known to many of our board members and others. ASIPP® has reached an agreement with Fedora to provide exclusive discounts on billing or revenue cycle management that will decrease practice costs and promote growth, or at least stop deterioration. It is not just a billing company; they streamline the billing and receivable process and constantly update payor regulations keeping your practice up to on date on a daily basis.
Some of the ASIPP® Billing Program highlights are below:
Up to 50% savings for ASIPP® members for their billing or revenue cycle management for their offices and surgery centers:
- Expertise in interventional pain management billing for all types of services
- 99% Clearing House Rate
- 95% First-Time Claim Passage
- 23.4 Average Days in A/R
- Eligibility and Benefits Verification
- Pre-Certification/Prior Authorization
- Denials and A/R Management
|
|
Join The Group Purchasing
Organization Today
|
|
ASIPP® has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value added services for the independent physician. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today. While the cost of contrast media has skyrocketed due to the single dose vial issue, because we have partnered with Henry Schein, this could enable you to purchase Omnipaque 240mg/50mL for slightly above $4.50.
Click on “view our discounted supplier prices” (Username: ASIPPmember and Password: Save) or click on the words "join for free now" and begin saving today!
|
|
FDA Head Says Any Approved COVID-19 Vaccine Will Be Safe
HealthDay News – Stephen Hahn, MD, the head of the US Food and Drug Administration, said Monday that the agency will not compromise safety when approving a COVID-19 vaccine, CNN reported.
That assurance was given during a video briefing with the American Medical Association. Because of how fast the FDA is working, some have questioned if the agency will weaken its usual rigor when it reviews data from clinical trials. “Let me assure you that we will not cut corners,” Hahn said. “All of our decisions will continue to be based on good science and the same careful deliberative processes we have always used when reviewing medical products.” Many Americans are wary of a vaccine. Hahn said he has seen surveys that show that many people will be reluctant to get vaccinated.
|
|
Essentials of Regenerative Medicine in Interventional
Pain Management
|
|
|
|
Essentials of Regenerative Medicine in Interventional Pain Management is a book to bring concise, collective, and comprehensive information to interventional pain physicians practicing regenerative medicine in managing chronic pain. Regenerative medicine is an integral part of interventional pain management within the definitions of interventional pain management and interventional techniques.
Each chapter contains an introduction of the subject, historical context,pathophysiology, applicability of regenerative medicine with its evidence base, indications, anatomy, technical aspects, complications, and precautions for each topic when available and applicable. This comprehensive book consists of 35 chapters, more than 350 figures, and 50 tables.
|
|
| ORDER | Essentials of Regenerative Medicine in IPM
|
|
Control Your Waiting Room TV
Customized waiting room TV exclusively for ASIPP® members. Create your own ad-free television broadcasts using our videos, custom informational slides and your own YouTube videos. Even add local weather reports, news and live messages.
|
|
|
|
|
|
GSIPP 16th Annual Pain Summit |
|
The Ritz-Carlton Reynolds Plantation
Lake Oconee
|
|
|
|
|
|
|
2020 12th Annual Scientific
Meeting
|
|
|
|
|
|
|
|
|
|
